Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 26

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 26
---
 (1,782 | ) |
| Shareholders’ equity:                |     |                      |         |   |     |       |         |   |     |          |         |   |
| Share capital and share premium      |     |                      |  25,570 |   |     |       |  29,398 |   |     |          |  30,725 |   |
| Warrants                             |     |                      |     459 |   |     |       |     459 |   |     |          |     459 |   |
| Share-based payment reserve          |     |                      |   2,250 |   |     |       |   2,250 |   |     |          |   2,250 |   |
| Accumulated other comprehensive loss |     |                      |     (21 | ) |     |       |     (21 | ) |     |          |     (21 | ) |
| Accumulated deficit                  |     |                      | (27,192 | ) |     |       | (27,192 | ) |     |          | (27,192 | ) |
| Total shareholders’ equity           |     |                      |   1,066 |   |     |       |   4,894 |   |     |          |   6,221 |   |
| Total capitalization                 |     |                      |   1,066 |   |     |       |   4,894 |   |     |          |   6,221 |   |

Unless otherwise indicated,
the number of common shares outstanding prior to and after this offering is based on 5,379,441 common shares outstanding as of July
31, 2025. The number of common shares referred to above to be outstanding after this offering and, unless otherwise indicated, the other
information in this prospectus, excludes as of such date:

| ● | 2,238,848 common shares issuable upon the exercise of warrants outstanding as of such date, at exercise prices ranging from $1.0777 to $243.75, all of which were vested as of such date;                                                                       |
| ● | 5,521 common shares issuable upon the exercise of options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average exercise price of $434.63, of which 5,509 were vested as of such date; and |
| ● | 88